Substance / Medication

Iron

Overview

Active Ingredient
iron
RxNorm CUI
90176

Indications

® Ferralet90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs.

Labeler: Mission Pharmacal CompanyUpdated: 2026-01-07T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

iron-containing Accidental overdose ofproducts is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

Contraindications

When this intervention should not be used

Hypersensitivity to any of the ingredients. Hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
The role of the iron-chelating agent deferoxamine in spinal cord injury: a systematic review and meta-analysis of preclinical studies.
Moradi Mehrnaz, Najibi Amirhossein, Moshfeghinia Reza et al. · Spine J · 2026
PMID: 40653020Meta-Analysis
Quantitative MRI iron load assessment in β-thalassemia patients beyond the liver and heart: A systematic review.
Almuqbel Mustafa M, Abousrafa Sarah, Omara Waad et al. · Eur J Radiol · 2026
PMID: 41260184Meta-Analysis
Oral iron supplements for children in malaria-endemic areas.
Itzkovich Michael, Neuberger Ami, Harris Itai et al. · Cochrane Database Syst Rev · 2026
PMID: 41510785Meta-AnalysisFull text (PMC)
Ferric Carboxymaltose Among Patients with Heart Failure and Iron Deficiency: An Updated Meta-Analysis of Randomized Controlled Trials.
Mohamed Ahmed Elmorsy, Gadelmawla Ahmed Farid, Kholeif Zeyad et al. · Cardiovasc Toxicol · 2026
PMID: 41524998Meta-Analysis
Global prevalence of iron deficiency anaemia among children aged 5-12 years: a systematic review and meta-analysis.
Sukwuttichai Pattarapan, Tidwong Nattapong, Chaipichit Natapohn et al. · J Glob Health · 2026
PMID: 41572874Meta-AnalysisFull text (PMC)
Recent Advances in Research on Iron Metabolism, Ferritin, and Hepcidin.
Polizzi Alessandro · Int J Mol Sci · 2026
PMID: 41596552Meta-Analysis
Intravenous Iron for Heart Failure: Updated Systematic Review and Meta-Analysis.
Techasatian Witina, Nishimura Yoshito, Tanariyakul Manasawee et al. · Angiology · 2025
PMID: 37916421Meta-Analysis
Iron-related Genes and Proteins Involved in Iron Homeostasis in Animal Models of Allergic Asthma: A Systematic Review.
Wafriy Che Ismail, Nor-Ashikin Mohamed Noor Khan, Kamsani Yuhaniza Shafinie et al. · Biol Trace Elem Res · 2025
PMID: 38717673Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Iron (substance)
SNOMED CT
3829006
UMLS CUI
C0302583
RxNorm CUI
90176
Labeler
Mission Pharmacal Company

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

1
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.